Product Details
Uptravi
Selexipag1200 mcg
Tablet
DIN/PIN/NPN
02451204
Manufacturer
Janssen Inc.
Formulary Listing Date
2023-04-28
Unit Price
70.5245
Amount MOH Pays
70.5245
Coverage Status
Exceptional Access Program Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
B01AC27
Interchangeable Products
NOLU Clinical Criteria
NOEAP Criteria
Therapeutic Class | Reimbursement Criteria |
---|---|
Pulmonary Arterial Hypertension | Selexipag
Drugs for Pulmonary Arterial Hypertension (PAH) under EAP
All requests (initial, renewal, monotherapy, combination therapy) for a PAH drug must come from one of the following recognized PAH referral centres:
Requests from other physicians/centres must include a recent (less than or equal to 3 months old) consult note/recommendation from a recognized PAH referral centre that supports the request; Out-of-province referral centre consults (e.g., from Winnipeg for patients in Northern Ontario) will also be considered on a case-by-case basis Initial Criteria: For the treatment of patients with pulmonary arterial hypertension (PAH) [WHO Group 1 Pulmonary hypertension] who meet all the following criteria:
Notes:
Case-by-case consideration may be provided for the following:
Exclusion Criteria: Combination therapy with prostacyclin or prostacyclin analog therapies and Selexipag will not be covered. Renewal criteria: Renewals will be provided for patients who remain under the care of a physician from a recognized PAH Centre (see list above) and who continue to benefit from therapy. Approval Durations: EAP Drug Request Form: |